Le Lézard
Classified in: Health, Science and technology
Subject: Personnel

Toragen, Inc. Announces Chief Medical Officer to Drive the Company's Clinical Development


Toragen Inc., a San Diego-based biotechnology company focused on developing, repurposing, and commercializing uniquely selective drugs targeting cancers caused by the human papillomavirus ("HPV"), today announced that Neil Clendeninn, MD, PhD, joined as Chief Medical Officer.

Dr. Clendeninn has worked for over 20 years in the pharmaceutical and biotechnology industry and has an established track record of successful drug development. Most recently Dr. Clendeninn served as the Senior Vice President and Chief Medical Officer of Heron Therapeutics, in San Diego, CA, where he established the clinical departments including Medical Affairs, Clinical Operations, Clinical Research and Biostatistics. He was instrumental in gaining the approval of SUSTOL, a long-acting granisetron formulation for chemotherapy-induced nausea and vomiting. Previously he held the position of Vice President of Clinical Affairs for Agouron Pharmaceuticals, of La Jolla, CA where he helped develop the anti-viral HIV protease inhibitor Viracept (Nelfinavir).

"We are thrilled to welcome Dr. Clendeninn to the Toragen team at such a critical time in our corporate growth," said Dr. Sandra Coufal, Toragen's CEO. "Dr. Clendininn's direct experience in clinical oncology, and his long career in drug development, including anti-virals, is an ideal match for Toragen, and I look forward to his leadership of our Phase I clinical trial."

About Toragen

Toragen, a pre-clinical stage biotechnology company, is targeting the root cause of virally induced cancers. https://toragen.com.


These press releases may also interest you

at 09:37
While scientific evidence has supported the health properties of tea's bioactive compounds, there is now guidance on how much of these nutrients we need to consume for health benefits. New guidelines published in Advances in Nutrition have...

at 09:35
SAMDI Tech, Inc., the industry's leading provider of label-free drug discovery solutions, today announced that Chief Scientific Officer Zachary Gurard-Levin, Ph.D., has been elected to the board of directors for the Society of Laboratory Automation...

at 09:31
Inizio, a strategic partner for companies in health and life sciences, has today announced the acquisition of Evolution Road, a digital innovation company in life science omnichannel, digital marketing and digital health strategy....

at 09:30
According to a new report published by UnivDatos Markets Insights, the Empty Capsules Market was valued at USD 2 billion in 2020 and is expected to grow at a CAGR of around 8% from 2022-2028. The analysis has been segmented into Type (Gelatin...

at 09:30
Trialjectory ("the Company''), an AI-powered decision support platform that democratizes patient access to advanced cancer treatments and empowers the pharmaceutical and biotech industry to execute more patient-centric clinical trials, announced...

at 09:30
ANEW MEDICAL, INC. ("ANEW" or "the Company") , a medical technology holding company announced that it has acquired an exclusive worldwide license from Universitat Autonomous de Barcelona (UAB) and affiliated institutions to a platform technology for...



News published on 7 october 2022 at 17:25 and distributed by: